Okubo Kenichi, Bando Toru, Miyahara Ryo, Sakai Hiroaki, Shoji Tsuyoshi, Sonobe Makoto, Fujinaga Takuji, Sato Kiyoshi, Wada Hiromi, Tanaka Toru
Department of Thoracic Surgery, Kyoto University Hospital, Shogoin, Kyoto, Japan.
J Thorac Oncol. 2009 Feb;4(2):203-7. doi: 10.1097/JTO.0b013e3181949c6a.
Management of pulmonary metastasis of non-small cell lung cancer (NSCLC) remains controversial. We reviewed our surgical treatment for pulmonary metastasis of NSCLC.
Seventy-six patients with pulmonary metastasis of NSCLC underwent pulmonary resections in two institutes during the past 10 years. Eighteen patients with simultaneous same lobe metastasis as the primary lesion underwent mostly lobectomies. Sixteen patients with simultaneous different lobe metastasis underwent combined margin-free resections. Forty-nine pulmonary metastasectomies were performed in 42 patients with recurrent lung cancer. Overall survival and disease-free survival in each group were examined, and factors affecting survivals were investigated.
In the patients with the same lobe metastasis 5-year survival was 79.6%, and median and 5-year disease-free survivals were 39.1 months and 41.3%. In the patients with simultaneous different lobe metastasis median survival and 5-year survival were 37.7 months and 30.7%, and median and 5-year disease-free survivals were 13.3 months and 12.5%, respectively. Multiple pulmonary metastasis and mediastinal node metastasis were identified as significant factors affecting survivals. In the patients with recurrent pulmonary metastasis median survival and 5-year survival were 40.0 months and 34.8%, and median and 5-year disease-free survivals were 23.7 months and 14.4%, respectively. Node metastasis, higher age, and shorter interval from the prior resection were identified as significant factors affecting survivals.
These findings suggest that the simultaneous same lobe metastasis is under the same indication for the primary lesion, and that the simultaneous different lobe metastasis and recurrent pulmonary metastasis should be removed in selected patients.
非小细胞肺癌(NSCLC)肺转移的治疗仍存在争议。我们回顾了我们对NSCLC肺转移的手术治疗。
在过去10年中,两所机构的76例NSCLC肺转移患者接受了肺切除术。18例与原发性病变同时发生同叶转移的患者大多接受了肺叶切除术。16例同时发生不同叶转移的患者接受了联合无瘤边缘切除术。42例复发性肺癌患者进行了49次肺转移瘤切除术。检查了每组的总生存率和无病生存率,并研究了影响生存率的因素。
同叶转移患者的5年生存率为79.6%,中位无病生存率和5年无病生存率分别为39.1个月和41.3%。同时发生不同叶转移的患者中位生存期和5年生存率分别为37.7个月和30.7%,中位无病生存期和5年无病生存率分别为13.3个月和12.5%。多发性肺转移和纵隔淋巴结转移被确定为影响生存率的重要因素。复发性肺转移患者的中位生存期和5年生存率分别为40.0个月和34.8%,中位无病生存期和5年无病生存率分别为23.7个月和14.4%。淋巴结转移、高龄和上次切除后间隔时间短被确定为影响生存率的重要因素。
这些发现表明,同时发生的同叶转移与原发性病变的适应证相同,对于同时发生的不同叶转移和复发性肺转移,应选择合适的患者进行切除。